169 related articles for article (PubMed ID: 38095707)
61. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
62. Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin.
Suppa A; Asci F; Saggio G; Marsili L; Casali D; Zarezadeh Z; Ruoppolo G; Berardelli A; Costantini G
Parkinsonism Relat Disord; 2020 Apr; 73():23-30. PubMed ID: 32222482
[TBL] [Abstract][Full Text] [Related]
63. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
64. A single-centre retrospective review of unilateral and bilateral Dysport injections in adductor spasmodic dysphonia.
Elmiyeh B; Prasad VM; Upile T; Saunders N; Youl BD; Epstein R; Rubin JS
Logoped Phoniatr Vocol; 2010 Apr; 35(1):39-44. PubMed ID: 20350075
[TBL] [Abstract][Full Text] [Related]
65. [Spasmodic Dysphonia].
Tokashiki R
Brain Nerve; 2023 Jan; 75(1):15-22. PubMed ID: 36574969
[TBL] [Abstract][Full Text] [Related]
66. A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia.
Zwirner P; Murry T; Woodson GE
Eur Arch Otorhinolaryngol; 1993; 250(5):271-6. PubMed ID: 8217128
[TBL] [Abstract][Full Text] [Related]
67. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
Nerurkar NK; Banu TP
J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
[TBL] [Abstract][Full Text] [Related]
68. Use of Botulinum Toxin in Spasmodic Dysphonia: A Review of Recent Studies.
Khan HA
Cureus; 2023 Jan; 15(1):e33486. PubMed ID: 36628391
[TBL] [Abstract][Full Text] [Related]
69. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ
Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821
[TBL] [Abstract][Full Text] [Related]
70. Botulinum toxin for the treatment of spasmodic dysphonia.
Gibbs SR; Blitzer A
Otolaryngol Clin North Am; 2000 Aug; 33(4):879-94. PubMed ID: 10918666
[TBL] [Abstract][Full Text] [Related]
71. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review.
Watts C; Nye C; Whurr R
Clin Rehabil; 2006 Feb; 20(2):112-22. PubMed ID: 16541931
[TBL] [Abstract][Full Text] [Related]
72. Effects of botulinum toxin type A injections on aerodynamic measures of spasmodic dysphonia.
Adams SG; Durkin LC; Irish JC; Wong DL; Hunt EJ
Laryngoscope; 1996 Mar; 106(3 Pt 1):296-300. PubMed ID: 8614192
[TBL] [Abstract][Full Text] [Related]
73. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Lerner MZ; Lerner BA; Patel AA; Blitzer A
Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
[TBL] [Abstract][Full Text] [Related]
74. The effect of unilateral thalamic deep brain stimulation on the vocal dysfunction in a patient with spasmodic dysphonia: interrogating cerebellar and pallidal neural circuits.
Poologaindran A; Ivanishvili Z; Morrison MD; Rammage LA; Sandhu MK; Polyhronopoulos NE; Honey CR
J Neurosurg; 2018 Feb; 128(2):575-582. PubMed ID: 28304188
[TBL] [Abstract][Full Text] [Related]
75. Spasmodic dysphonia: botulinum toxin injection after recurrent nerve surgery.
Ludlow CL; Naunton RF; Fujita M; Sedory SE
Otolaryngol Head Neck Surg; 1990 Feb; 102(2):122-31. PubMed ID: 2113236
[TBL] [Abstract][Full Text] [Related]
76. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
[TBL] [Abstract][Full Text] [Related]
77. Identification of symptoms for spasmodic dysphonia and vocal tremor: a comparison of expert and nonexpert judges.
Barkmeier JM; Case JL; Ludlow CL
J Commun Disord; 2001; 34(1-2):21-37. PubMed ID: 11322567
[TBL] [Abstract][Full Text] [Related]
78. [Botulinum toxin efficacy in the treatment of patients with spasmodic dysphonia].
Svetel M; Vasić M; Tomić G; Stanković P; Stojanović M; Dragasević N; Dergenc R; Vukasinović M; Pekmezović T; Petrović I; Kostić V
Vojnosanit Pregl; 2007 Oct; 64(10):671-5. PubMed ID: 18041568
[TBL] [Abstract][Full Text] [Related]
79. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
80. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox).
Brin MF; Blitzer A; Fahn S; Gould W; Lovelace RE
Mov Disord; 1989; 4(4):287-96. PubMed ID: 2811888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
